Developmental toxicity evaluation of ibuprofen and tolmetin administered in triple daily doses to wistar CRL:(WI)WUBR rats

Birth Defects Research Part B - Developmental and Reproductive Toxicology

Volumn 71, Issue 5, 2004, Pages 321-330

  Burdan, Franciszek ^a,b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b Experimental Teratology Unit   (Poland)

Author keywords

COX 1; COX 2; Cyclooxygenase; Developmental anomalies; Ibuprofen; Midline defect; Nonsteroidal anti inflammatory drugs; NSAID; Pregnancy; Prenatal toxicity; Rat; Tolmetin; Umbilical hernia; Ventricular septal defects

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE; ASPARTATE AMINOTRANSFERASE; IBUPROFEN; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN; TOLMETIN; UREA;

ABORTION; ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CONGENITAL MALFORMATION; CONTROLLED STUDY; FEMALE; FETOTOXICITY; FETUS; FETUS WEIGHT; GASTROINTESTINAL TOXICITY; HEART VENTRICLE SEPTUM DEFECT; INTRAUTERINE GROWTH RETARDATION; LIVER INJURY; MALE; NONHUMAN; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RAT; SKELETON MALFORMATION; STOMACH LESION; UMBILICAL HERNIA;

ANIMALS; ASPIRIN; BODY WEIGHT; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FETAL DEVELOPMENT; FETAL GROWTH RETARDATION; FETUS; HEART SEPTAL DEFECTS, VENTRICULAR; IBUPROFEN; MATERNAL EXPOSURE; PREGNANCY; RATS; RATS, WISTAR; TOLMETIN;

ANIMALIA;

EID: 8644279770     PISSN: 15429733     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdrb.20018     Document Type: Article

References (66)

1. Adams SS, Bough RG, Cliffe EE, Lessel B, Mills RF. 1969. Absorption, distribution and toxicity of ibuprofen. Toxicol Appl Pharmacol 15:310-330.
2. Alano MA, Ngougmna E, Ostrea EM Jr, Konduri GG. 2001. Analysis of nonsteroidal anti-inflammatory drugs in meconium and its relation to persistent pulmonary hypertension of the newborn. Pediatrics 107:519-523.
3. Barry WS, Meinzinger MM, Howse CR. 1984. Ibuprofen overdose and exposure in utero: results from a postmarketing voluntary reporting system. Am J Med 77:35-39.
4. Beck SL. 1990. Prenatal and postnatal assessment of maneb-exposed CD-1 mice. Reprod Toxicol 4:283-290.
5. Bodendorfer TW, Briggs GG, Gunning JE. 1979. Obtaining drug exposure histories during pregnancy. Am J Obstet Gynecol 135:490-494.
6. Brideau C, Kargman S, Liu S, Dallob AL, Ehrich EW, Rodger W, Chan CC. 1996. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm Res 45:68-74.
7. Briggs GG, Freeman R, Yaffe SJ. 1998. Drugs in Pregnancy and lactation: a reference guide to fetal and neonatal risk, 5th ed. Baltimore: Williams & Wilkins.
8. Burdan F. 2000. Somatic and skeleton development of rat fetuses following in-utero exposure to isopropylantipyrine (propyphenazone) during the second trimester of gestation. Folia Morphol 59:317-322.
9. Burdan F. 2002a. Effects of prenatal exposure to combination of acetaminophen, isopropylantipyrine and caffeine on intrauterine development in rats. Hum Exp Toxicol 21:25-31.
10. Burdan F. 2002b. Formation of the knee joint after prenatal propyphenazone (Isopropylantipyrine) administration. Cells Tissues Organs 171:145-151.
11. Burdan F. 2004a. Influence of selective and nonselective cyclooxygenase-2 inhibitors on embryonal and fetal development, in particular skeleton formation. Habilitation Dissertation, Medical University of Lublin. Lublin: Wschod Agencja Uslugowa Inc. p 1-109.
12. Burdan F. 2004b. Developmental effects of propyphenazone in analgesic and antipyretic combination with caffeine or paracetamol. Hum Exp Toxicol 23:235-244.
13. Burdan F, Dudka J, Szumilo J, Korobowicz A, Klepacz L. 2003. Prenatal effect of DuP-697: the irreversible, highly selective cyclooxygenase-2 inhibitor. Reprod Toxicol 17:413-419.
14. Burdan F, Szumilo J, Kiepacz R, Dudka J, Korobowicz A, Tokarska E, Cendrowska-Pinkosz M, Madej B, Klepacz L. 2004. Gastrointestinal and hepatic toxicity of selective and nonselective cyclooxygenase-2 inhibitors in pregnant and nonpregnant rats. Pharmacol Res 50:533-543.
15. Cappon GD, Cook JC, Hurtt ME. 2003a. Relationship between cyclooxygenase 1 and 2 selective inhibitors and fetal development when administered to rats and rabbits during the sensitive periods for heart development and midline closure. Birth Defects Res Part B Dev Reprod Toxicol 68:47-56.
16. Cappon GD, Gupta U, Cook JC, Tassinari MS, Hurtt ME. 2003b. Comparison of the developmental toxicity of aspirin in rabbits when administered throughout organogenesis or during sensitive windows of development. Birth Defects Res Part B Dev Reprod Toxicol 68:38-46.
17. Chahoud I, Buschmann J, Clark R, Druga A, Falke H, Faqi A, Hansen E, Heinrich-Hirsch B, Hellwig J, Lingk W, Parkinson M, Paumgartten FJ, Pfeil R, Platzek T, Scialli AR, Seed J, Stahlmann R, Ulbrich B, Wu X, Yasuda M, Younes M, Solecki R. 1999a. Classification terms in developmental toxicology: need for harmonisation. Report of the Second Workshop on the Terminology in Developmental Toxicology Berlin, 27-28 August 1998. Reprod Toxicol 13:77-82.
18. Chahoud I, Ligensa A, Dietzel L, Faqi AS. 1999b. Correlation between maternal toxicity and embryo/fetal effects. Reprod Toxicol 13:375-381.
19. Christian MS. 2001. Test methods for assessing female reproductive and developmental toxicology. In: Hayes AW, editor. Principles and method of toxicology, 4th ed. Philadelphia: Taylor & Francis. p 1301-1381.
20. Claudio L, Bearer CF, Wallinga D. 1999. Assessment of the U.S. Environmental Protection Agency methods for identification of hazards to developing organisms, Part II: The developmental toxicity testing guideline. Am J Int Med 35:554-563.
21. Cleves MA, van Savell H, Raj S, Zhao W, Correa A, Werler MM, Habbs CA. 2004. National Birth Defects Prevention Study. Maternal Use of Acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs), and muscular ventricular septal defects. Birth Defects Res Part A Clin Mol Teratol 70:107-113.
22. Cook JC, Jacobson CF, Gao F, Tassinari MS, Hurtt ME, DeSesso JM. 2003. Analysis of the nonsteroidal anti-inflammatory drug literature for potential developmental toxicity in rats and rabbits. Birth Defects Res Part B Dev Reprod Toxicol 68:5-26.
23. Czeizel A, Racz J. 1990. Evaluation of drug intake during pregnancy in the Hungarian vase-control surveillance of congenital anomalies. Teratology 42:505-512.
24. Dannhardt G, Kiefer W. 2001. Cyclooxygenase inhibitors: current status and future prospects. Eur J Med Chem 36:109-126.
25. DevTox 2004. http://www.DevTox.org. Accessed 12 February 2004.
26. Elli M, Gaffuri B, Frigerio A, Zanardelli M, Covirti D, Candiani M, Vignali M. 2001. Effects of single dose of ibuprofen lysinate before embryo transfer on pregnancy rates in cows. Reproduction 121:151-154.
27. Ericson A, Kallen BAJ. 2001. Nonsteroidal anti-inflammatory drugs in early pregnancy. Reprod Toxicol 15:371-375.
28. Fritz H. 1975. Prenatal ossification in rabbits as indicative of fetal maturity. Teratology 11:313-319.
29. Golovanova IV, Skosyreva AM, Sharova SA, Guskova TA. 1985. Tolerance of some nonsteroidal anti-inflammatory drugs by experimental animals in pregnancy. Farmakol Toksikol 48:66-69.
30. Gupta I, Thmas KJ, Datta H, Mathur VS. 1984. Effect of ibuprofen and naproxen on implantation and pregnancy in rat. Ind J Exp Biol 22:282-283.
31. Gupta U, Cook JC, Tassinari MS, Hurtt ME. 2003. Comparison of developmental toxicity of aspirin (acetylosalicylic acid) in rats using selected dosing paradigms. Birth Defects Res Part B Dev Reprod Toxicol 68:27-37.
32. Hayes EC, Rock JA. 2002. COX-2 inhibitors and their role in gynecology. Obstet Gynecol Surv 57:768-780.
33. Hickok DE, Hollenbach KA, Reilley SF, Nyberg DA. 1989. The association between decreased amniotic fluid volume and treatment with non-steroidal anti-inflammatory agents for preterm labor. Am J Obstet Gynecol 160:1525-1526.
34. Jeffrey P, Tucker G, Bye A, Crewe HK, Wright PA. 1991. The site of inversion of R(-)-ibuprofen: studies using rat in-situ isolated perfused intestine/liver preparations. J Pharm Pharmacol 43:715-720.
35. Johnson DC, Chatteerjee S. 1995. The role of arachidonic acid and/or its metabolites in embryo implantation inhibited by epidermal growth factor (EGF). Prostagland Leukot Fatty Acids 52:29-35.
36. Khera KS. 1981. Common fetal aberrations and their teratogenic significance: a review. Fundam Appl Toxicol 1:13-18.
37. Kozer E, Costei AM, Boskovic R, Nulman I, Nikfar S, Koren G. 2003. Effects of aspirin consumption during pregnancy on pregnancy outcomes:meta-analysis. Birth Defects Res Part B Dev Reprod Toxicol 68:70-84
38. Li DK, Lu L, Odouli R. 2003. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage. BMJ 327:368-371.
39. Manson JM, Kang YJ. 1994. Test methods for assessing female reproductive and developmental toxicity. In: Hayes AW, editor. Principles and method of toxicology. 3rd ed. New York: Raven Press. p 989-1037.
40. Martinez-Frias ML, Rodriguez-Pinilia E, Prieto L. 1997. Prenatal exposure to salicylates and gastroschisis: a case-control study. Teratology 56:241-243.
41. Nishimura K, Fukagawa S, Shigematsu K. 1977. (Teratogenicity study of 1-methyl-5-p-toluoylpyrrole-2-acetate sodium dihydrate (tolmentin sodium) in rabbits). Iykuhin Kenkyu 8:158-164.
42. Olesen C, Sorensen HT, de Jong-van den Berg L, Olsen J, Steffensen FH. 1999a. Prescribing during pregnancy and lactation with reference to the Swedish classification system. A population-based study among Danish women. The Euromap Group. Acta Obstet Gynecol Scand 78:686-692.
43. Olesen C, Steffensen FH, Nielsen GL, de Jong-van den Berg L, Olsen J, Sorensen HT. 1999b. Drug use in first pregnancy and lactation: a population-based survey among Danish women. The EUROMAP group. Eur J Clin Pharmacol 55:139-144.
44. Olesen C, Sondergaard C, Thrane N, Nielsen GL, de Jong-van den Berg L, Olsen J, EuroMAP Group. 2001. Do pregnant women report use of dispensed medications? Epidemiology 12:497-501.
45. Olsen J, Czeizel A, Sorensen HT, Nielsen GL, de Jong van den Berg LT, Irgens LM, Olesen C, Pedersen L, Larsen H, Lie RT, de Vries CS, Bergman U. 2002. How do we best detect toxic effects of drugs taken during pregnancy? A EuroMap paper. Drug Saf 25:21-32.
46. Ono M, Hoshida F, Nagase M, Asami K. 1982a. Reproductive studies of ibuprofen by rectal administration. (2) Teratogenicity study in rats. Oyo Yakuri 24:531-538.
47. Ono M, Ogawa Y, Ogihara K, Nagase M, Asami K. 1982b. Reproduction studies of ibuprofen by rectal administration. (1) Fertility study in rats. Oyo Yakuri 24:467-473.
48. Ostensen M, Skomsvoll JF. 2004. Anti-inflammatory pharmacotherapy during pregnancy. Expert Opin Pharmacother 5:571-580.
49. PDR 1998. Physicians' desk reference, 52nd ed. Montvale: Medical Economics Company. p. 1536-1545; 2056-2058.
50. Sabater J, Domenech J, Obach R. 1992. Pharmacokinetic study of tolmetin in the rat. Drug Res 42:950-953.
51. Sattari S, Jamali F. 1994. Evidence of absorption rate dependency of ibuprofen inversion in the rat. Chirality 6:435-439.
52. Scialli AR. 1995. Teratology. In: Craighead JE, editor. Pathology of environmental and occupational disease. St. Louis: Mosby. p. 537-588.
53. Scialli AR, Buelke-Sam JL, Chambers CD, Friedman JM, Kimmel CA, Polifka JE, Tassinari MS. 2004. Communicating risk during pregnancy: A workshop on the use of data from animal developmental toxicity studies in pregnancy labels for drugs. Birth Defects Res Part A Clin Mol Teratol 70:7-12.
54. Solecki R, Burgin H, Buschmann J, Clark R, Duverger M, Fialkowski O, Guittin P, Hazelden KP, Hellwig J, Hoffmann E, Hofmann T, Hubel U, Khalil S, Lingk W, Mantovani A, Moxon M, Muller S, Parkinson M, Paul M, Paumgaitten F, Pfeil R, Platzek T, Rauch-Ernst M, Scheevelenbos A, Seed J, Talsness CE, Yasuda M, Younes M, Chahoud I. 2001. Harmonisation of rat fetal skeletal terminology and classification. Report of the Third Workshop on the Terminology in Developmental Toxicology. Reprod Toxicol 15:713-721.
55. Solecki R, Bergmann B, Burgin H, Buschmann J, Clark R, Druga A, Van Duijnhoven EA, Duverger M, Edwards J, Freudenberger H, Guittin P, Hakaite P, Heinrich-Hirsch B, Hellwig J, Hofmann T, Hubel U, Khalil S, Klaus A, Kudicke S, Lingk W, Meredith T, Moxon M, Muller S, Paul M, Paumgartten F, Rohrdanz E, Pfeil R, Rauch-Ernst M, Seed J, Spezia F, Vickers C, Woelffel B, Chahoud I. 2003. Harmonization of rat fetal external and visceral terminology and classification. Report of the Fourth Workshop on the Terminology in Developmental Toxicology. Berlin, 14-16 September 2000. Reprod Toxicol 17:625-637.
56. Stanfield KM, Bell RR, Lisowski AR, English ML, Saldeen SS, Khan KN. 2003. Expression of cyclooxygenase-2 in embryonic and fetal tissues during organogenesis and late pregnancy. Birth Defects Res Part A Clin Mol Teratol 67:54-58.
57. Streck RD, Kumpf SW, Ozolins TR, Stedman DB. 2003. Rat embryos express transcripts for cyclooxygenase-1 and carbonic anhydrase-4, but not for cyclooxygenase-2, during organogenesis. Birth Defects Res Part B Dev Reprod Toxicol 68:57-69.
58. Tassinari MS, Cook JC, Hurtt ME. 2003. NSAIDs and developmental toxicity. Birth Defects Res Part B Dev Reprod Toxicol. 68:3-4.
59. Tegeder I, Pfeilschifter J, Geisslinger G. 2001. Cyclooxygenase- independent action of cyclooxygenase inhibitors. FASEB J 15, 2057-2072.
60. Trofs CP, Katz EA, Bateson TF, Lam PK, Curry CJ. 1996. Maternal medications and environmental exposures as risk factor for gastroschisis. Teratology 54:84-92.
61. Vane JR, Bakhle YS, Botting RM. 1998. Cyclooxygease 1 and 2. Annu Rev Roxicol 38:97-120.
62. Walser S, Hruby R, Hesse E, Heinzl H, Mascher H. 1997. Preliminary toxicokinetic study with different crystal forms of S (-t-)-ibuprofen (dexibuprofen) and R,S-ibuprofen in rats. Drug Res 47:750-754.
63. Weerasekera DR, Bennett S. 1992. Adjustments to the Mantel-Haenszel test for data from stratifies multistage surveys. Stat Med 11:603-616.
64. Werler MM, Mitchell AA, Shapiro S. 1992a. First trimester maternal mediction use in relation to gastroschisis. Teratology 45:361-367.
65. Werler MM, Mitchell AA, Shapiro S. 1992b. Demographic, reproductive, medical, and environmental factors in relation to gastroschisis. Teratology 45:353-360.
66. Williams LJ, Correa A, Rasmussen S. 2004. Maternal lifestale factors and risk for ventricular septal defects. Birth Defects Res Part B Dev Reprod Toxicol 70:59-64.